Kalon Biotherapeutics tells BioPharma Reporter that within 14 months it expects the completion of the $91 million vaccine plant it is building with GlaxoSmithKline ($GSK) in Texas. Kalon is a private company born out of the Texas A&M University System. The Texas plant is one of three getting financial support from the U.S. which will be able have them ramp up vaccines for government use in case of a pandemic. Story | More